ABBV
AbbVie Inc. · Healthcare · Drug Manufacturers - General
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q2 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 183 | +6 | 1.07B | $270.09B | +9 | −2 |
| Q1 2026 | 179 | -3 | 1.05B | $227.15B | +2 | −6 |
| Q4 2025 | 181 | -3 | 1.14B | $259.75B | +1 | −3 |
| Q3 2025 | 27 | 0 | 673.15M | $155.83B | — | −1 |
| Q2 2025 | 25 | +2 | 519.81M | $96.45B | +2 | — |
| Q1 2025 | 20 | 0 | 175.76M | $36.80B | — | — |
| Q4 2024 | 20 | 0 | 178.61M | $31.72B | — | — |
| Q3 2024 | 19 | 0 | 95.00M | $18.73B | +1 | −1 |
| Q2 2024 | 19 | — | 90.79M | $15.55B | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passief) | 36.68M | — | $6.28B | 0.6% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passief) | 36.68M | — | $6.28B | 0.6% | n/c | 1 | SEC ↗ |
| 3 | Norges Bank ✦ (passief) | 22.48M | — | $3.86B | 0.6% | n/c | 1 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 10.94M | — | $1.88B | 0.2% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 10.94M | — | $1.88B | 0.2% | n/c | 1 | SEC ↗ |
| 6 | Capital World Investors ✦ | 10.28M | — | $1.76B | 0.3% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 2.88M | — | $494.42M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 2.88M | — | $494.42M | 0.1% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 2.88M | — | $494.42M | 0.1% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 2.88M | — | $494.42M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 2.88M | — | $494.42M | 0.1% | n/c | 1 | SEC ↗ |
| 12 | Wellington Management ✦ | 2.88M | — | $494.42M | 0.1% | n/c | 1 | SEC ↗ |
| 13 | Wellington Management ✦ | 2.88M | — | $494.42M | 0.1% | n/c | 1 | SEC ↗ |
| 14 | Adage Capital Partners ✦ | 1.42M | — | $243.61M | 0.5% | n/c | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 1.40M | — | $237.81M | 0.4% | n/c | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 1.40M | — | $237.81M | 0.4% | n/c | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 1.40M | — | $237.81M | 0.4% | n/c | 1 | SEC ↗ |
| 18 | Renaissance Technologies ✦ | 1.30M | — | $223.78M | 0.4% | n/c | 1 | SEC ↗ |
| 19 | Millennium Management ✦ | 980.23K | — | $168.13M | 0.1% | n/c | 1 | SEC ↗ |
| 20 | D. E. Shaw & Co. ✦ | 918.63K | — | $157.56M | 0.2% | n/c | 1 | SEC ↗ |
| 21 | D. E. Shaw & Co. ✦ | 918.63K | — | $157.56M | 0.2% | n/c | 1 | SEC ↗ |
| 22 | Marshall Wace ✦ | 885.91K | — | $151.95M | 0.2% | n/c | 1 | SEC ↗ |
| 23 | Bridgewater Associates ✦ | 288.52K | — | $49.49M | 0.3% | n/c | 1 | SEC ↗ |
| 24 | Arrowstreet Capital ✦ | 183.07K | — | $31.40M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | Gotham Asset Management ✦ | 46.08K | — | $7.90M | 0.1% | n/c | 1 | SEC ↗ |
| 26 | Fisher Asset Management ✦ | 39.80K | — | $6.83M | 0.0% | n/c | 1 | SEC ↗ |
| 27 | Two Sigma Investments ✦ | 17.07K | — | $2.93M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | GAMCO Investors ✦ | 14.75K | — | $2.53M | 0.0% | n/c | 1 | SEC ↗ |
| 29 | Dodge & Cox ✦ | 11.01K | — | $1.89M | 0.0% | n/c | 1 | SEC ↗ |
| 30 | Harris Associates (Oakmark) ✦ | 1.49K | — | $256,079 | 0.0% | n/c | 1 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 1 houders, 82.20K aandelen, $17,877 gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 32.71K aand · $8.18M
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie